Gufic BioSciences Ltd
Pharmaceuticals & Biotechnology | Small Cap
Gufic BioSciences Ltd demonstrates a mixed financial performance. The company shows strong solvency and profitability, indicating a solid foundation and efficient use of capital. Revenue and asset growth are also positive signs. However, liquidity is a concern, suggesting potential difficulties in meeting short-term obligations. Efficiency ratios are low, which could point to issues with asset utilization. While the company maintains a good dividend coverage, declines in operating profit, EPS, and net income growth raise concerns about future earnings sustainability. Overall, the company's strengths in profitability and solvency are tempered by weaknesses in liquidity and efficiency, requiring careful monitoring of operational performance to ensure long-term stability.
Latest Report
View AllThe Latest Reports Are Not Available at the Moment. We’ll Notify You Once They’re Available.
Latest News
View AllThe Latest News Is Not Available at the Moment. We’ll Notify You Once It’s Available.
- Valuation MetricsNeutral
- Market Metrics
- Stock Reports
- Stock News
- Growth Ratio4.80
- Financial Ratio3.80
- Profitability Ratio9.80
- Efficiency Ratio2.67
- Coverage Ratio8.80
- Solvency Ratio9.50
- Liquidity Ratio4.26
- Peer Assessment
- Management AssessmentBalanced
- Risk AssessmentBalanced
- 1 HourBearish
- 2 HoursBearish
- 4 HoursBearish
- 1 DayBullish
- 1 WeekBullish
- 1 MonthBullish
Gufic BioSciences Ltd demonstrates a mixed financial performance. The company shows strong solvency and profitability, indicating a solid foundation and efficient use of capital. Revenue and asset growth are also positive signs. However, liquidity is a concern, suggesting potential difficulties in meeting short-term obligations. Efficiency ratios are low, which could point to issues with asset utilization. While the company maintains a good dividend coverage, declines in operating profit, EPS, and net income growth raise concerns about future earnings sustainability. Overall, the company's strengths in profitability and solvency are tempered by weaknesses in liquidity and efficiency, requiring careful monitoring of operational performance to ensure long-term stability.
Overall Valuation Score
P/E RATIO (TTM)
56.39
Industry Median
28.62
Small Cap Median
27.17
P/E RATIO
55.51
P/B RATIO
5.36
Industry Median
3.17
Small Cap Median
2.62
P/S RATIO
3.83
Industry Median
3.42
Small Cap Median
2.55
Others
PEG RATIO
0.00
EV/EBITDA RATIO
23.67
The Calculations Shown Above Are Based on the Last Traded Price (LTP) of ₹355.25 as on Jun 19, 2026.
Unlock Live Chart
Please login to view interactive real-time technical charts powered by TradingView.
Markets Depth NSE
Buy Orders
Bid
Quantity
Orders
No buy depth
Total
0
0
Sell Orders
Ask
Quantity
Orders
No sell depth
Total
0
0
Markets Today NSE
High
0.00
Low
0.00
Open
0.00
Close
0.00
Prev Close
0.00
Avg Price
0.00
Volume
0
Last Traded Quantity
0
Last Traded Time
N/A
Price Movement Indicator
0.00
Today's Low
0.00
Today's High
The company's growth ratios present a mixed picture. Strong revenue and asset growth is offset by declines in operating profit, EPS, and net income growth. While the company is expanding its top-line and asset base, profitability is suffering. This suggests potential issues with cost management or pricing strategies. Maintaining revenue and asset growth while improving profitability will be critical for sustainable long-term performance.
| Growth Ratios | Mar 2024 | Mar 2025 | Mar 2026 |
|---|---|---|---|
| Revenue Growth Rate | 1.61 | 15.12 | |
| Operating Profit Growth Rate | -9.33 | 11.03 | |
| Earnings Per Share (EPS) Growth | -19.09 | -7.91 | |
| Asset Growth Rate | 6.95 | 14.8 | |
| Net Income Growth Rate | -18.6 | -8.57 |
Revenue Growth Rate
Operating Profit Growth Rate
Earnings Per Share (EPS) Growth
Asset Growth Rate
Net Income Growth Rate
The company's financial ratios present a mixed view. While adjusted EPS is average, cash EPS, book value per share, dividend per share, and capital expenditures are low. This could point to challenges in earnings quality, shareholder value, and investment in future growth. Improving cash earnings, increasing book value, and making strategic capital investments will be important for enhancing overall financial performance and shareholder returns.
| Financial Ratios | Mar 2024 | Mar 2025 | Mar 2026 |
|---|---|---|---|
| Adjusted Earnings Per Share (Adjusted EPS) | 8.8 | 7 | 6.4 |
| Cash Earnings Per Share (Cash EPS) | 10.3 | 9.1 | 9.5 |
| Book Value Per Share | 53.3 | 60.1 | 66.5 |
| Dividend Per Share (DPS) | 0.09 | 0.07 | 0 |
| Capital Expenditures (CapEx) | 108.1 | 70.8 | 31.2 |
Adjusted Earnings Per Share (Adjusted EPS)
Cash Earnings Per Share (Cash EPS)
Book Value Per Share
Dividend Per Share (DPS)
Capital Expenditures (CapEx)
The company demonstrates strong profitability. Excellent margins across gross profit, operating profit, and net profit indicate efficient operations and effective pricing strategies. High returns on capital employed, equity, and assets confirm the company's ability to generate substantial profits from its investments. This robust profitability reflects sound management and a competitive edge in the healthcare services sector.
| Profitability Ratios | Mar 2024 | Mar 2025 | Mar 2026 |
|---|---|---|---|
| Gross Profit Margin | 16.48 | 14.02 | 12.71 |
| Return on Capital Employed (ROCE) | 18.92 | 13 | 12 |
| Return on Equity (ROE) | 16.14 | 11.65 | 9.62 |
| Return on Assets (ROA) | 13.72 | 11.63 | 11.25 |
| Operating Margin | 18.59 | 16.59 | 16 |
| Net Margin | 10.66 | 8.54 | 6.78 |
Gross Profit Margin
Return on Capital Employed (ROCE)
Return on Equity (ROE)
Return on Assets (ROA)
Operating Margin
Net Margin
The company's efficiency ratios indicate poor asset utilization. Low turnover ratios for fixed assets, inventory, and receivables suggest that the company is not effectively converting its investments into sales. High days sales in inventory and receivable days further highlight inefficiencies in managing inventory and collecting payments. This suggests a need to streamline operations and improve asset management to enhance overall performance.
| Efficiency Ratios | Mar 2024 | Mar 2025 | Mar 2026 |
|---|---|---|---|
| Fixed Asset Turnover Ratio | 5.08 | 1.62 | 1.92 |
| Inventory Turnover Ratio | 3.37 | 3.38 | 3.05 |
| Receivables Turnover Ratio | 2.45 | 2.54 | 3.08 |
| Days Sales in Inventory Ratio | 108.31 | 107.99 | 119.67 |
| Receivable Days | 149 | 143.7 | 118.51 |
| Capital Turnover Ratio | 1.15 | 1.08 | 1.19 |
Fixed Asset Turnover Ratio
Inventory Turnover Ratio
Receivables Turnover Ratio
Days Sales in Inventory Ratio
Receivable Days
Capital Turnover Ratio
The company exhibits strong coverage ratios. A solid interest coverage ratio indicates a comfortable ability to meet its debt obligations, reducing financial risk. The excellent equity dividend coverage ratio demonstrates a strong capacity to sustain dividend payments to shareholders. These coverage metrics reflect a stable financial position and a commitment to meeting obligations and rewarding investors.
| Coverage Ratios | Mar 2024 | Mar 2025 | Mar 2026 |
|---|---|---|---|
| Interest Coverage Ratio | 7.82 | 4.76 | 3.35 |
| Equity Dividend Coverage Ratio | 100 | 100 |
Interest Coverage Ratio
Equity Dividend Coverage Ratio
The company exhibits strong solvency, indicating a solid financial structure. Low debt and high equity ratios suggest a conservative approach to financing, reducing financial risk. The debt-to-asset ratio further supports this, reflecting a substantial asset base relative to debt. This strong solvency provides a stable foundation, enabling the company to pursue long-term growth opportunities with reduced vulnerability to economic downturns.
| Solvency Ratios | Mar 2024 | Mar 2025 | Mar 2026 |
|---|---|---|---|
| Debt Ratio | 0.24 | 0.21 | 0.16 |
| Debt to Equity Ratio | 0.32 | 0.27 | 0.19 |
| Equity Ratio | 0.76 | 0.79 | 0.84 |
| Debt To Asset Ratio | 0.16 | 0.13 | 0.09 |
Debt Ratio
Debt to Equity Ratio
Equity Ratio
Debt To Asset Ratio
The company's liquidity position shows mixed signals. While the quick ratio is average, indicating some ability to meet short-term obligations, the current and operating cash flow ratios suggest potential difficulties in managing immediate liabilities. The low cash ratio is a concern, reflecting limited cash reserves. This blended performance indicates a need for careful management of current assets and liabilities to ensure the company can comfortably meet its short-term obligations.
| Liquidity Ratios | Mar 2024 | Mar 2025 | Mar 2026 |
|---|---|---|---|
| Current Ratio | 1.6 | 1.55 | 1.5 |
| Quick Ratio | 1.09 | 1.03 | 0.91 |
| Cash Ratio | 0.03 | 0.07 | 0.14 |
| Operating Cash Flow Ratio | -0.02 | 0.3 | 0.08 |
Current Ratio
Quick Ratio
Cash Ratio
Operating Cash Flow Ratio
Peer Comparison empowers investors to evaluate a company against its industry peers using key financial metrics like P/E ratio, EPS, and profit margins. It helps identify whether a company is overvalued, undervalued, or performing in line with competitors. Investors can use this data to spot opportunities, assess risks, and make informed decisions. This contextual view adds depth beyond standalone company analysis.
| NO | Company Name | Health Score | P/E Ratio | Valuation | OPM | EPS | Latest Profit & Loss |
|---|---|---|---|---|---|---|---|
| 1 | Jagsonpal Pharmaceuticals Ltd | 8.51 | 33.01 | Overvalued | 58.00 | 6.42 | 43.00 |
| 2 | Amrutanjan Health Care Ltd | 8.25 | 77.37 | Highly Overvalued | 31.00 | 20.03 | 21.00 |
| 3 | Windlas Biotech Ltd | 7.52 | 25.92 | Neutral | 105.00 | 32.19 | 66.00 |
| 4 | Innova Captab Ltd | 7.36 | 38.55 | Overvalued | 243.00 | 14.63 | 141.00 |
| 5 | Hikal Ltd | 7.13 | -51.71 | Neutral | 220.00 | -3.95 | -49.00 |
| 6 | RPG Life Sciences Ltd | 7.12 | 32.70 | Neutral | 147.00 | 69.64 | 115.00 |
| 7 | Morepen Laboratories Ltd | 7.12 | 28.61 | Neutral | 126.00 | 1.21 | 96.00 |
| 8 | Alembic Ltd | 7.06 | 7.28 | Undervalued | 90.00 | 4.85 | 317.00 |
| 9 | Syncom Formulations (India) Ltd | 6.92 | 17.27 | Undervalued | 77.00 | 0.81 | 76.00 |
| 10 | Sigachi Industries Ltd | 6.49 | 11.55 | Highly Undervalued | 54.00 | -2.08 | -83.00 |
| 11 | SMS Pharmaceuticals Ltd | 5.94 | 34.77 | Neutral | 171.00 | 9.35 | 102.00 |
| 12 | Gufic BioSciences Ltd | 5.49 | 55.51 | Neutral | 151.00 | 6.30 | 64.00 |
| 13 | Dishman Carbogen Amcis Ltd | 5.38 | 27.45 | Neutral | 566.00 | -2.45 | 97.00 |
| 14 | IOL Chemicals & Pharmaceuticals Ltd | 5.31 | 27.76 | Undervalued | 269.00 | 4.69 | 138.00 |
| 15 | Indoco Remedies Ltd | 5.26 | -22.79 | Neutral | 142.00 | -0.61 | -99.00 |
| 16 | Aarti Drugs Ltd | 5.07 | 17.34 | Undervalued | 309.00 | 18.54 | 195.00 |
| 17 | Orchid Pharma Ltd | 4.85 | 241.74 | Neutral | 41.00 | 8.91 | 21.00 |
| 18 | Sequent Scientific Ltd | 4.61 | 293.05 | Overvalued | 162.00 | 0.63 | 32.00 |
| 19 | Sun Pharma Advanced Research Company Ltd | 4.35 | 4.97 | Neutral | 1599.00 | 47.83 | 1553.00 |
| 20 | Solara Active Pharma Sciences Ltd | 4.34 | -274.68 | Neutral | 187.00 | -1.50 | -7.00 |
| 21 | Zota Health Care Ltd | 3.97 | -61.25 | Neutral | 19.00 | 8.06 | -74.00 |
The management of Gufic BioSciences demonstrates a mixed performance. A strong promoter holding indicates confidence, but declining profit growth and operating profit margins raise concerns. While revenue growth is positive, capital efficiency, as reflected in ROCE and ROE, is moderate. Increasing interest expenses and a declining net profit also present challenges. The company's consistent dividend payout is a positive aspect. Overall, management effectiveness is mixed due to profitability and operational efficiency challenges despite revenue growth.
| Category | Metric | Value | Assessment |
|---|---|---|---|
| PROS | Promoter Holding | 72.51% | High promoter confidence and alignment |
| Dividend Payout | 1% | Consistent profit sharing | |
| CONS | Declining Profit Growth | -21% (TTM) | Profit growth is declining |
| Declining OPM | 12.87% (Mar 2025 Qtr) | Operational efficiency is decreasing |
Financial Performance & Growth
Gufic BioSciences shows modest sales growth but faces challenges in sustaining profit growth. The compounded sales growth (TTM) is 2%, with a YOY sales growth of 1.63% in Mar 2025. However, the compounded profit growth (TTM) is -21%, indicating a decline in profitability. Quarterly sales have fluctuated, with a recent value of ₹205.02 Cr. in Mar 2025. The operating profit margin (OPM) has decreased to 16% in Mar 2025 from 18% in Mar 2024. The net profit has also declined to ₹70 Cr. in Mar 2025 from ₹86 Cr. in Mar 2024. The contribution from other income is minimal, suggesting that the company's profit primarily comes from core operations. The recent decline in profit growth and OPM raises concerns about the company's ability to maintain profitability.
| Metric | 2024 | 2025 |
|---|---|---|
| Sales Growth % | - | 1.63% |
| Profit Growth % | - | -21% |
| OPM % | 18% | 16% |
Capital Efficiency & Returns
Gufic BioSciences exhibits moderate capital efficiency. The Return on Capital Employed (ROCE) is 13% for Mar 2025. The Return on Equity (ROE) stands at 12% for the last year. These metrics suggest that the company is generating reasonable returns on its capital and equity. However, there is room for improvement to enhance capital efficiency and returns.
| Metric | Value |
|---|---|
| ROCE % | 13% |
| ROE % | 12% |
Financial Health & Prudence
Gufic BioSciences' financial health indicates a moderate level of leverage. The company has borrowings of ₹336 Cr. as of Mar 2025. Interest expenses have increased from ₹15 Cr. in Mar 2024 to ₹23 Cr. in Mar 2025. The company consistently shares profits through dividends, with a dividend payout of 1%. The increase in interest expenses and borrowings must be monitored to ensure financial stability.
| Metric | 2024 | 2025 |
|---|---|---|
| Borrowings (Cr) | 333 | 336 |
| Interest (Cr) | 15 | 23 |
Strategic & Operational Indicators
Gufic BioSciences shows mixed operational efficiency. Debtor Days have decreased from 149 in Mar 2024 to 140 in Mar 2025, indicating efficient collection of receivables. However, Inventory Days have increased from 188 to 211, suggesting potential issues with inventory management. Days Payable have slightly decreased from 156 to 155. The Cash Conversion Cycle has increased from 181 to 197 days. The mix of improvements and challenges suggests the need for further optimization of operational strategies.
| Metric | 2024 | 2025 |
|---|---|---|
| Debtor Days | 149 | 140 |
| Inventory Days | 188 | 211 |
| Days Payable | 156 | 155 |
| Cash Conversion Cycle | 181 | 197 |
The risk assessment for Gufic BioSciences is rated as Orange due to several factors. The declining profit growth and OPM raise concerns about financial performance. The increase in inventory days and cash conversion cycle indicate potential inefficiencies in working capital management. Additionally, the rise in interest expenses and borrowings could strain financial health. Therefore, while the company exhibits some strengths, these identified risks warrant a cautious approach.
Regulatory compliance cost trends
There are no details about specific regulatory compliance costs.
0 Credits RemainingUnlock Deep Technical Insights in Seconds Only with Dhanarthi AI
Overall Score
Strong Bearish
Bearish
Neutral
Bullish
Strong Bullish
Bearish
Market Sentiment
Analysis Driven By 26 Technical Indicators From The 1 Hour Timeframe
Trend Score
Strong Bearish
Bearish
Neutral
Bullish
Strong Bullish
Strong Bearish
Momentum Score
Strong Bearish
Bearish
Neutral
Bullish
Strong Bullish
Neutral
Volatility Score
Strong Bearish
Bearish
Neutral
Bullish
Strong Bullish
Bullish
Volume Score
Strong Bearish
Bearish
Neutral
Bullish
Strong Bullish
Neutral
- IndicatorValueSignal
- SMA 10356.57Bearish
- SMA 20360.37Bearish
- SMA 50361.79Bearish
- EMA 10356.84Bearish
- EMA 20359.14Bearish
- EMA 50361.45Bearish
- DEMA 10354.32Bearish
- DEMA 20355.75Bearish
- DEMA 50362.21Bearish
- TEMA 10354.08Bearish
- TEMA 20354.17Bearish
- TEMA 50355.52Bearish
- MACD-2.68Bearish
- ADX17.55Weak Trend
- IndicatorValueSignal
- RSI35.69Neutral
- CCI-83.55Neutral
- ROC 9-0.83Bearish
- ROC 14-3.07Bearish
- ROC 25-2.52Bearish
- Stoch K14.46Oversold
- Stoch D14.49Oversold
- IndicatorValueSignal
- BB Upper369.58Neutral
- BB Middle360.36Neutral
- BB Lower351.15Neutral
- ATR4.10Low Volatility
- IndicatorValueSignal
- MFI21.35Neutral
Overall Score
Strong Bearish
Bearish
Neutral
Bullish
Strong Bullish
Bearish
Market Sentiment
Analysis Driven By 26 Technical Indicators From The 2 Hours Timeframe
Trend Score
Strong Bearish
Bearish
Neutral
Bullish
Strong Bullish
Strong Bearish
Momentum Score
Strong Bearish
Bearish
Neutral
Bullish
Strong Bullish
Bullish
Volatility Score
Strong Bearish
Bearish
Neutral
Bullish
Strong Bullish
Bullish
Volume Score
Strong Bearish
Bearish
Neutral
Bullish
Strong Bullish
Neutral
- IndicatorValueSignal
- SMA 10359.06Bearish
- SMA 20362.28Bearish
- SMA 50365.59Bearish
- EMA 10358.36Bearish
- EMA 20360.78Bearish
- EMA 50357.81Bearish
- DEMA 10355.11Bearish
- DEMA 20358.16Bearish
- DEMA 50370.08Bearish
- TEMA 10353.90Bullish
- TEMA 20354.58Bearish
- TEMA 50364.45Bearish
- MACD-2.23Bearish
- ADX16.79Weak Trend
- IndicatorValueSignal
- RSI39.80Neutral
- CCI-109.25Oversold
- ROC 9-3.07Bearish
- ROC 14-3.41Bearish
- ROC 250.11Bullish
- Stoch K11.89Oversold
- Stoch D13.30Oversold
- IndicatorValueSignal
- BB Upper372.80Neutral
- BB Middle362.28Neutral
- BB Lower351.76Neutral
- ATR6.16Low Volatility
- IndicatorValueSignal
- MFI36.48Neutral
Overall Score
Strong Bearish
Bearish
Neutral
Bullish
Strong Bullish
Bearish
Market Sentiment
Analysis Driven By 26 Technical Indicators From The 4 Hours Timeframe
Trend Score
Strong Bearish
Bearish
Neutral
Bullish
Strong Bullish
Bearish
Momentum Score
Strong Bearish
Bearish
Neutral
Bullish
Strong Bullish
Bearish
Volatility Score
Strong Bearish
Bearish
Neutral
Bullish
Strong Bullish
Bullish
Volume Score
Strong Bearish
Bearish
Neutral
Bullish
Strong Bullish
Neutral
- IndicatorValueSignal
- SMA 10362.23Bearish
- SMA 20366.18Bearish
- SMA 50338.06Bullish
- EMA 10360.47Bearish
- EMA 20359.79Bearish
- EMA 50343.99Bullish
- DEMA 10357.78Bearish
- DEMA 20366.53Bearish
- DEMA 50368.29Bearish
- TEMA 10354.32Bearish
- TEMA 20359.38Bearish
- TEMA 50N/AN/A
- MACD3.79Bearish
- ADX37.70Strong Trend
- IndicatorValueSignal
- RSI48.07Neutral
- CCI-106.56Oversold
- ROC 9-3.50Bearish
- ROC 14-2.47Bearish
- ROC 25-1.73Bearish
- Stoch K22.90Neutral
- Stoch D25.53Neutral
- IndicatorValueSignal
- BB Upper385.02Neutral
- BB Middle366.18Neutral
- BB Lower347.34Neutral
- ATR10.83Low Volatility
- IndicatorValueSignal
- MFI52.40Neutral
Overall Score
Strong Bearish
Bearish
Neutral
Bullish
Strong Bullish
Bullish
Market Sentiment
Analysis Driven By 33 Technical Indicators From The 1 Day Timeframe
Trend Score
Strong Bearish
Bearish
Neutral
Bullish
Strong Bullish
Bullish
Momentum Score
Strong Bearish
Bearish
Neutral
Bullish
Strong Bullish
Bullish
Volatility Score
Strong Bearish
Bearish
Neutral
Bullish
Strong Bullish
Bullish
Volume Score
Strong Bearish
Bearish
Neutral
Bullish
Strong Bullish
Neutral
- IndicatorValueSignal
- SMA 10367.64Bearish
- SMA 20348.73Bullish
- SMA 50315.73Bullish
- SMA 100304.90Bullish
- SMA 200325.88Bullish
- EMA 10361.10Bearish
- EMA 20348.99Bullish
- EMA 50326.30Bullish
- EMA 100318.80Bullish
- EMA 200326.05Bullish
- DEMA 10369.86Bearish
- DEMA 20371.71Bearish
- DEMA 50346.25Bullish
- DEMA 100318.62Bullish
- DEMA 200308.26Bullish
- TEMA 10364.39Bearish
- TEMA 20376.75Bearish
- TEMA 50366.20Bearish
- TEMA 100335.02Bullish
- TEMA 200303.45Bullish
- MACD16.55Bearish
- ADX43.16Strong Trend
- IndicatorValueSignal
- RSI56.75Neutral
- CCI37.31Neutral
- ROC 147.13Bullish
- ROC 2524.66Bullish
- Stoch K52.73Neutral
- Stoch D58.69Neutral
- IndicatorValueSignal
- BB Upper400.63Neutral
- BB Middle348.73Neutral
- BB Lower296.84Neutral
- ATR17.94Low Volatility
- IndicatorValueSignal
- MFI77.36Neutral
Overall Score
Strong Bearish
Bearish
Neutral
Bullish
Strong Bullish
Bullish
Market Sentiment
Analysis Driven By 21 Technical Indicators From The 1 Week Timeframe
Trend Score
Strong Bearish
Bearish
Neutral
Bullish
Strong Bullish
Strong Bullish
Momentum Score
Strong Bearish
Bearish
Neutral
Bullish
Strong Bullish
Neutral
Volatility Score
Strong Bearish
Bearish
Neutral
Bullish
Strong Bullish
Bearish
Volume Score
Strong Bearish
Bearish
Neutral
Bullish
Strong Bullish
Strong Bearish
- IndicatorValueSignal
- SMA 20302.99Bullish
- SMA 50331.67Bullish
- EMA 20316.41Bullish
- EMA 50327.67Bullish
- DEMA 20316.44Bullish
- DEMA 50309.55Bullish
- TEMA 20331.37Bullish
- TEMA 50296.79Bullish
- MACD3.11Bullish
- ADX23.36Weak Trend
- IndicatorValueSignal
- RSI59.44Neutral
- CCI94.80Neutral
- ROC 1432.99Bullish
- ROC 256.38Bullish
- Stoch K86.89Overbought
- Stoch D74.86Neutral
- IndicatorValueSignal
- BB Upper354.51Overbought
- BB Middle302.99Neutral
- BB Lower251.48Neutral
- ATR28.54High Volatility
- IndicatorValueSignal
- MFI84.38Overbought
Overall Score
Strong Bearish
Bearish
Neutral
Bullish
Strong Bullish
Bullish
Market Sentiment
Analysis Driven By 25 Technical Indicators From The 1 Month Timeframe
Trend Score
Strong Bearish
Bearish
Neutral
Bullish
Strong Bullish
Bullish
Momentum Score
Strong Bearish
Bearish
Neutral
Bullish
Strong Bullish
Bullish
Volatility Score
Strong Bearish
Bearish
Neutral
Bullish
Strong Bullish
Bearish
Volume Score
Strong Bearish
Bearish
Neutral
Bullish
Strong Bullish
Neutral
- IndicatorValueSignal
- SMA 6303.09Bullish
- SMA 12331.85Bullish
- SMA 24360.74Bearish
- EMA 6311.00Bullish
- EMA 12324.89Bullish
- EMA 24330.86Bullish
- DEMA 6300.26Bullish
- DEMA 12304.90Bullish
- DEMA 24342.27Bearish
- TEMA 6306.71Bullish
- TEMA 12289.47Bullish
- TEMA 24312.33Bullish
- MACD31.80Bearish
- ADX27.38Strong Trend
- IndicatorValueSignal
- RSI53.25Neutral
- CCI12.37Neutral
- ROC 252.11Bullish
- ROC 5034.08Bullish
- Stoch K29.90Neutral
- Stoch D53.81Neutral
- IndicatorValueSignal
- BB Upper462.61Neutral
- BB Middle358.28Neutral
- BB Lower253.95Neutral
- ATR57.84High Volatility
- IndicatorValueSignal
- MFI50.59Neutral